Abstract
Pylera® comprises three (bismuth substrate potassium + metronidazole + tetracycline hydrochloride) of four components of bismuth-based quadruple therapy for the eradication of Helicobacter pylori (H. pylori) in a single capsule. The 10-day regimen consists of the relatively convenient administration of Pylera® four times daily + twice-daily administration of the proton pump inhibitor omeprazole. This regimen provides an effective, well tolerated and relatively convenient option for administering bismuth-based quadruple therapy, which a recommended first- and second-line treatment for H. pylori eradication. The Pylera® regimen effectively eradicated H. pylori, regardless of the treatment line, the resistance of the bacterial strain to metronidazole and/or clarithromycin, the type of gastric disease and the country of treatment. The regimen is well tolerated, with a tolerability profile that is consistent with those of the individual components taken separately.
References
Abadi ATB. Helicobacter pylori treatment: new perspectives using current experience. J Glob Antimicrob Resist. 2017;8:123–30.
Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347(15):1175–86.
McColl KE. Clinical practice: Helicobacter pylori infection. N Engl J Med. 2010;362(17):1597–604.
Schöttker B, Adamu MA, Weck MN, et al. Helicobacter pylori infection is strongly associated with gastric and duodenal ulcers in a large prospective study. Clin Gastroenterol Hepatol. 2012;10(5):487–93.
Smith S, Boyle B, Brennan D, et al. The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. Eur J Gastroenterol Hepatol. 2017;29(5):552–9.
Zagari RM, Romano M, Ojetti V, et al. Guidelines for the management of Helicobacter pylori infection in Italy: the III Working Group Consensus Report 2015. Dig Liv Dis. 2015;47:903–12.
Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection: the Maastricht V/ Florence Consensus Report. Gut. 2017;66(1):6–30.
Gisbert JP, Molina-Infante J, Amador J, et al. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol. 2016;39(10):697–721.
Pylera® (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride): summary of product characteristics. Dublin: Allergan Pharmaceuticals International Limited; 2016.
Pylera® (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride): US prescribing information. Irvine: Allergan USA, Inc.; 2017.
Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65(5):870–8.
Wagstaff AG, Benfield P, Monk JP. Colloidal bismuth subcitrate: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs. 1988;36(2):132–57.
De Francesco V, Zullo A, Hassan C, et al. Mechanisms of Helicobacter pylori antibiotic resistance: an updated appraisal. World J Gastrointest Pathophysiol. 2011;2(3):35–41.
Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011;377(9769):905–13.
Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol. 2003;98(3):562–7.
O’Morain C, Borody T, Farley A, et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther. 2003;17(3):415–20.
Alboraie M, Saad M, Al-Ali J, et al. Quadruple therapy versus standard triple therapy for eradication of Helicobacter pylori in Kuwait. Arab J Gastroenterol. 2015;16(3–4):131–5.
Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2014;40(2):171–7.
Muller N, Amiot A, Le Thuaut A, et al. Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains. Clin Res Hepatol Gastroenterol. 2016;40(4):517–24.
Di Ciaula A, Scaccianoce G, Venerito M, et al. Eradication rates in Italian subjects heterogeneously managed for Helicobacter pylori infection: time to abandon empiric treatment in southern Europe. J Gastrointest Liver Dis. 2017;26(2):129–37.
Tursi A, Di Mario F, Franceschi M, et al. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: a first Italian experience in clinical practice. Helicobacter. 2017. doi:10.1111/hel.12371.
McNicholl AG, Megraud F, Tepes B, et al. Pan-European Registry on Helicobacter pylori Management (Hp-EuReg): interim analysis of the single-capsule bismuth quadruple treatment (Pylera®) [abstract no. PW2.2]. Helicobacter. 2016;21(Suppl 1):73–4.
Lainé-Cessac P, Bourneau-Martin D, Drablier G, et al. Neurological adverse effects of PYLERA®: the risk of bismuth encephalopathy is not yet confirmed and remains potential and theorical [abstract no. PM1-015]. Fundam Clin Pharmacol. 2016;30(Suppl 1):28.
Acknowledgements
The manuscript was reviewed by: M. Alboraie, Department of Internal Medicine, Al-Azhar University, Cairo, Egypt; A. Tursi, Gastroenterology Service, Azienda Sanitaria Locale della provincia di Barletta, Andria, Italy. During the peer review process, the marketing authorisation holder of Pylera® was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Conflict of interest
K.A. Lyseng-Williamson is a salaried employee(s) of Adis/Springer, is responsible for the article content and declares no conflicts of interest. Additional information about this Adis Drug Q&A can be found at http://www.medengine.com/Redeem/9E48F0602D77F03E.
Rights and permissions
About this article
Cite this article
Lyseng-Williamson, K.A. Pylera® (bismuth subcitrate potassium/metronidazole/tetracycline hydrochloride) in the eradication of Helicobacter pylori infection: a profile of its use in Europe. Drugs Ther Perspect 33, 311–320 (2017). https://doi.org/10.1007/s40267-017-0417-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-017-0417-7